[{"NetIncomeLoss_2_Q2_USD":-7659000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":44199000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":323000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":42218000.0,"Liabilities_0_Q2_USD":21378000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2_Q2_USD":37000.0,"ProceedsFromRepaymentsOfDebt_2_Q2_USD":-16743000.0,"OperatingLeaseLiability_0_Q2_USD":917000.0,"PreferredStockSharesOutstanding_0_Q2_shares":1016000.0,"MarketableSecuritiesCurrent_0_Q2_USD":158555000.0,"DepreciationAndAmortization_2_Q2_USD":271000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":6630000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":3310000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"InterestPaidNet_2_Q2_USD":339000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-990000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-41991000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":1245650.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1_Q2_shares":127300.0,"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q2_USD":7769000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":46000.0,"AssetsCurrent_0_Q2_USD":207010000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":23000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":587000.0,"CommonStockSharesIssued_0_Q2_shares":34994790.0,"Assets_0_Q2_USD":210676000.0,"ShareBasedCompensation_2_Q2_USD":2487000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":1029000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1_Q2_pure":0.0048,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_Q2_pure":0.0077,"NetIncomeLossAvailableToCommonStockholdersBasic_2_Q2_USD":-7437000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q2_USD":-170000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":312000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":22511000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":10720000.0,"InterestIncomeDepositsWithFinancialInstitutions_2_Q2_USD":2191000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":945000.0,"EarningsPerShareBasic_2_Q2_USD":-0.22,"EarningsPerShareBasic_1_Q2_USD":0.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":-459000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":34084508.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":34979282.0,"GainsLossesOnExtinguishmentOfDebt_2_Q2_USD":-988000.0,"GainsLossesOnExtinguishmentOfDebt_1_Q2_USD":-988000.0,"AccountsReceivableNetCurrent_0_Q2_USD":1786000.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":102456000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_Q2_pure":0.68,"IncomeTaxExpenseBenefit_2_Q2_USD":-40000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":-39000.0,"CommonStockValue_0_Q2_USD":397652000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":-1054000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_Q2_shares":31412.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1_Q2_shares":5144.0,"ForeignCurrencyTransactionGainLossBeforeTax_2_Q2_USD":424000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q2_USD":662000.0,"ForeignCurrencyTransactionGainLossUnrealized_2_Q2_USD":-23000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":85750000.0,"AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1_Q2_USD":1472000.0,"CommonStockNoParValue_0_Q2_USD":null,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":105798000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1_Q2_pure":0.68,"DeferredIncomeTaxAssetsNet_0_Q2_USD":290000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_Q2_USD":7.5,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q2_USD":8.27,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":19444000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":1009000.0,"CommonStockSharesOutstanding_0_Q2_shares":34994790.0,"EarningsPerShareDiluted_2_Q2_USD":-0.22,"EarningsPerShareDiluted_1_Q2_USD":0.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":146773000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-7699000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-214000.0,"MarketableSecuritiesUnrealizedGainLoss_2_Q2_USD":532000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-23856000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":34084508.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":34979282.0,"LiabilitiesCurrent_0_Q2_USD":21055000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-257314000.0,"InterestExpense_2_Q2_USD":484000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":2470000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":28000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.0375,"PreferredStockNoParValue_0_Q2_USD":null,"NetIncomeLossAvailableToCommonStockholdersDiluted_2_Q2_USD":-7437000.0,"NetIncomeLossAvailableToCommonStockholdersDiluted_1_Q2_USD":-170000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":44199000.0,"StockIssuedDuringPeriodSharesStockOptionsExercised_2_Q2_shares":153042.0,"StockIssuedDuringPeriodSharesStockOptionsExercised_1_Q2_shares":54716.0,"OperatingLeasePayments_2_Q2_USD":311000.0,"PreferredStockSharesIssued_0_Q2_shares":1016000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":2347000.0,"NetIncomeLoss_1_Q2_USD":-175000.0,"InterestExpense_1_Q2_USD":154000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-17760000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0_Q2_shares":2114647.0,"VariableLeaseCost_2_Q2_USD":267000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":28000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-225000.0,"OperatingIncomeLoss_2_Q2_USD":-8679000.0,"OperatingIncomeLoss_1_Q2_USD":-646000.0,"AccountsPayableTradeCurrent_0_Q2_USD":1633000.0,"InvestmentIncomeInterest_2_Q2_USD":2028000.0,"InvestmentIncomeInterest_1_Q2_USD":912000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_Q2_pure":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1_Q2_pure":0.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":12692000.0,"PreferredStockValue_0_Q2_USD":7732000.0,"DeferredIncomeTaxExpenseBenefit_2_Q2_USD":-52000.0,"OperatingLeaseCost_2_Q2_USD":260000.0,"VariableLeaseCost_1_Q2_USD":132000.0,"OperatingLeaseCost_1_Q2_USD":151000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":1830000.0,"AmortizationOfDebtDiscountPremium_2_Q2_USD":216000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":594000.0,"OperatingExpenses_2_Q2_USD":29141000.0,"OperatingExpenses_1_Q2_USD":14030000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.22,"EarningsPerShareBasicAndDiluted_1_Q2_USD":0.0,"ProfitLoss_2_Q2_USD":-7659000.0,"StockholdersEquity_0_Q2_USD":189298000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":1016000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_2_Q2_USD":20462000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_1_Q2_USD":13384000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q2_shares":4595432.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":210676000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":222000.0,"Ticker":"XENE","CIK":"1582313","name":"XENON PHARMACEUTICALS INC.","OfficialName":"Xenon Pharmaceuticals Inc. Common Shares","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"1764405075.0","Country":"Canada","Sector":"nan","Industry":"nan","Market":"NASDAQ","SP500":"nan","filed":"20200806"}]